MULTIMODAL VISIBLE POLYMER EMBOLIZATION MATERIAL

• US 20120184642A1
• Filed: 07/06/2010
• Published: 07/19/2012
• Est. Priority Date: 07/07/2009
• Status: Abandoned Application

• Current Assignee: Hagit Aviv, Shlomo Margel, Soenke Bartling
• Original Assignee: Hagit Aviv, Shlomo Margel, Soenke Bartling
• Inventors: Margel, Shlomo, Bartling, Soenke, Aviv, Hagit
• Application Number:
  US13/382,352
• Publication Number:
  US 20120184642A1
• Time in Patent Office: Days
• US Class Current: 523/113
• CPC Class Codes: A61B 5/0035 adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
• CPC Class Codes: A61B 5/0515 Magnetic particle imaging
• CPC Class Codes: A61B 5/416 the spleen
• CPC Class Codes: A61B 6/5235 combining images from the same or different ionising radiation imaging techniques, e.g. PET and CT
• CPC Class Codes: A61B 6/5247 combining images from an ionising-radiation diagnostic technique and a non-ionising radiation diagnostic technique, e.g. X-ray and ultrasound
• CPC Class Codes: A61B 8/4281 characterised by sound-transmitting media or devices for coupling the transducer to the tissue
• CPC Class Codes: A61B 8/4416 related to combined acquisition of different diagnostic modalities, e.g. combination of ultrasound and X-ray acquisitions
• CPC Class Codes: A61K 49/0002 General or multifunctional contrast agents, e.g. chelated agents
• CPC Class Codes: A61K 49/0419 Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
• CPC Class Codes: A61K 49/0438 Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
• CPC Class Codes: A61K 49/0442 Polymeric X-ray contrast-enhancing agent comprising a halogenated group
• CPC Class Codes: A61K 49/048 Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
• CPC Class Codes: A61K 49/1821 coated or functionalised microparticles or nanoparticles
• CPC Class Codes: A61K 49/225 Microparticles, microcapsules gas-filled to be classified in A61K49/223
• CPC Class Codes: A61K 51/1244 microparticles or nanoparticles, e.g. polymeric nanoparticles
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates to embolization material for therapeutic use, wherein said material is visible via more than one imaging technique.

Claims

1. Embolization material for therapeutic use, wherein said material is visible via more than one imaging technique.

2. The embolization material of claim 1, wherein said material comprises at least one polymer component and at least one inorganic component, and wherein said material is visible with high contrast via more than one imaging technique.

3. The embolization material of claim 2, wherein said material is visible via at least one of the following imaging techniques:

a) X-ray computed tomography (CT)/projectional radiography and magnetic resonance imaging (MRI),

b) X-ray computed tomography (CT)/projectional radiography and ultrasonography (US),

c) X-ray computed tomography (CT)/projectional radiography and single photon emission computed tomography (SPECT),

d) X-ray computed tomography (CT)/projectional radiography and positron emission tomography (PET),

e) magnetic resonance imaging (MRI) and ultrasonography (US),

f) magnetic resonance imaging (MRI) and single photon emission computed tomography (SPECT),

g) magnetic resonance imaging (MRI) and positron emission tomography (PET),

h) X-ray computed tomography (CT)/projectional radiography and magnetic particle imaging, or

i) a combination of two or more of said imaging techniques.

4. The embolization material of claim 3, wherein said material is visible via three different imaging techniques at the same time.

5. The embolization material of claim 2, wherein the at least one polymer component is selected from the group of polyacrylate, polymethacrylate, polyacrylamide, polymethacrylamide, acrylate polymer, polyamide, polysiloxane, polyester, polyurethane, polyvinyl ether, polyvinyl ester, copolymers comprising as monomers a (meth)acrylic-derivative and/or a meth(acrylamide)-derivative carrying a cleavable iodine substituted side group, or mixtures thereof.

6. The embolization material according to claim 5, wherein the at least one polymer component comprises a copolymer of glycidyl-methacrylate and a (meth)acrylic-derivative carrying a cleavable iodine substituted aromatic side group.

7. The embolization material of claim 5, wherein the at least one inorganic component comprises a radio-opaque element selected from the group of calcium, iron, iodine, xenon, barium, ytterbium, silver, gold, bismuth, cesium, thorium, or tungsten, and a magnetic resonance imaging (MRI) visible component selected from the group iron oxides, gadolinium, manganese based agents, or perfluorocarbons.

8. The embolization material of claim 7, said material comprising a radio-opaque element, and a magnetic resonance imaging (MRI) visible component, and additionally components enabling detection via ultrasonography (US) selected from the group of gas aggregates or gas bubbles, microbubbles, microspheres of human albumin, microparticles of galactose, perflenapent, microspheres of phospholipids, and/or sulfur hexafluoride.

9. The embolization material of claim 1, wherein said material comprises an X-ray visible, iodine containing core, and a MRI visible, ultra small paramagnetic iron oxide based coating, and wherein said material is selected from magnetic iron oxide/Poly((2-methacryloyloxyethyl-(2,3,5-triiodobenzoate))-(glycidyl-methacrylate)) particles.

10. The embolization material of claim 9, said material exhibiting different particle sizes ranging from 30 μ

m to 900 μ

m.

11. The embolization material of claim 9, said material exhibiting different particle sizes ranging from 40 μ

m to 200 μ

m.

12. The embolization material of claim 11, wherein the first imaging technique of detection is selected from X-ray computed tomography (CT)/projectional radiography, or magnetic resonance imaging (MRI).

13. The embolization material of claim 12, wherein the second imaging technique of detection is selected from ultrasonography (US) and nuclear medical imaging techniques.

14. A kit of at least two parts for the preparation of embolization material according to claim 2, the kit comprising as one part at least one polymer component and as second part at least one inorganic component.

15. A method for the preparation of the embolization material of claim 2 comprising the steps of:

a) synthesizing the at least one polymer component,

b) synthesizing the at least one inorganic component, and

c) optionally synthesizing a component detectable via ultrasonography, and

d) combining the at least one polymer component of step a with the at least one inorganic component of step b, and optionally with the component of step c, and thus, obtaining the embolization material.

16. The embolization material of claim 3, wherein the at least one polymer component is selected from the group of polyacrylate, polymethacrylate, polyacrylamide, polymethacrylamide, acrylate polymer, polyamide, polysiloxane, polyester, polyurethane, polyvinyl ether, polyvinyl ester, copolymers comprising as monomers a (meth)acrylic-derivative and/or a meth(acrylamide)-derivative carrying a cleavable iodine substituted side group, or mixtures thereof.

17. The embolization material of claim 16, wherein the at least one inorganic component comprises a radio-opaque element selected from the group of calcium, iron, iodine, xenon, barium, ytterbium, silver, gold, bismuth, cesium, thorium, or tungsten, and a magnetic resonance imaging (MRI) visible component selected from the group iron oxides, gadolinium, manganese based agents, or perfluorocarbons.

18. The embolization material of claim 17, said material comprising a radio-opaque element, and a magnetic resonance imaging (MRI) visible component, and additionally components enabling detection via ultrasonography (US) selected from the group of gas aggregates or gas bubbles, microbubbles, microspheres of human albumin, microparticles of galactose, perflenapent, microspheres of phospholipids, and/or sulfur hexafluoride.

19. The embolization material of claim 18, wherein said material comprises an X-ray visible, iodine containing core, and a MRI visible, ultra small paramagnetic iron oxide based coating, and wherein said material is selected from magnetic iron oxide/Poly((2-methacryloyloxyethyl-(2,3,5-triiodobenzoate))-(glycidyl-methacrylate)) particles.

20. The embolization material of claim 2, wherein said material comprises an X-ray visible, iodine containing core, and a MRI visible, ultra small paramagnetic iron oxide based coating, and wherein said material is selected from magnetic iron oxide/Poly((2-methacryloyloxyethyl-(2,3,5-triiodobenzoate))-(glycidyl-methacrylate)) particles.